(COG ACNS0831) Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years
Description: 

This study proposes to answer the question of whether the administration of maintenance chemotherapy following radiation will improve event free and overall survival or whether it will only result in additional toxicity. Neurologic, neuropsychological and endocrine long-term sequelae of surgery, cRT and maintenance chemotherapy will be assessed. This study will use a comprehensive genetic approach in order to create a molecular classification for ependymoma and to identify the genetic alterations underlying the biological and clinical behavior of various subsets of this tumor.

Study Number: 

NCG 186710

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01096368

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.